[go: up one dir, main page]

WO2007068163A1 - Peptides inhibiteurs de la fusion du vih et leur utilisation - Google Patents

Peptides inhibiteurs de la fusion du vih et leur utilisation Download PDF

Info

Publication number
WO2007068163A1
WO2007068163A1 PCT/CN2006/001323 CN2006001323W WO2007068163A1 WO 2007068163 A1 WO2007068163 A1 WO 2007068163A1 CN 2006001323 W CN2006001323 W CN 2006001323W WO 2007068163 A1 WO2007068163 A1 WO 2007068163A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
peptide
seq
hiv
amino acids
Prior art date
Application number
PCT/CN2006/001323
Other languages
English (en)
Chinese (zh)
Inventor
Qiuyun Dai
Jianwei Cheng
Yuxian He
Mingxin Dong
Junming He
Liankang Yu
Original Assignee
Institute Of Biotechnology, The Academy Of Military Medical Sciences, Pla
Sichuan Kechuang Pharmaceutical Corporation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute Of Biotechnology, The Academy Of Military Medical Sciences, Pla, Sichuan Kechuang Pharmaceutical Corporation Limited filed Critical Institute Of Biotechnology, The Academy Of Military Medical Sciences, Pla
Publication of WO2007068163A1 publication Critical patent/WO2007068163A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates to a class of polypeptides that inhibit viral fusion, and more particularly to a class of polypeptides that inhibit HIV viral fusion.
  • the invention also relates to the use of the polypeptide.
  • HIV Human Immunodeficiency Virus
  • HAV Human Respiratory Syncytial Virus
  • Hepatitis B Virus The life cycle of some enveloped viruses, such as Human Immunodeficiency Virus (HIV), Human Respiratory Syncytial Virus and Hepatitis B Virus, can be divided into four parts: virus and cell membrane fusion, genetic material entering the cell. Reverse transcription of viral DNA and integration into the chromosome of the host cell; transcription, translation, modification of viral proteins; assembly and budding of viral particles. What these viruses have in common is that there is a membrane fusion process in the life cycle, and the structures of the proteins involved in the fusion process are similar.
  • the drugs currently used to treat HIV infection can be divided into three categories: reverse transcriptase inhibitors, protease inhibitors and entry inhibitors (including fusion inhibitors), respectively.
  • Link Jiang S., et al., Curr. Pharra. Des., 2002, 8 (8): 563-580).
  • Reverse transcriptase inhibitors and protease inhibitors are prone to drug resistance during use and are an important reason for the limited use of these two classes of drugs.
  • long-term use of these two types of inhibitors such as abnormal fat distribution, osteoporosis and other toxic side effects are also very obvious (Zhou Wei, et al. Chinese AIDS and STD. 2005, 11 (1): 73-75).
  • HIV entry inhibitors inhibit the entry of HIV into cells, where fusion inhibitors act on viral and cell membrane fusion processes. Clinically, it has been found that the HIV virus fusion inhibitor alone can greatly reduce the viral load and has low side effects. HIV fusion inhibitors can also be combined with reverse transcriptase inhibitors and protease inhibitors to reduce the use of both drugs, thereby reducing side effects and preventing the emergence of new resistant strains.
  • the entry inhibitor acts on the stage before the virus enters the cell, ie from the beginning of the virus and cell contact to the membrane fusion.
  • This phase consists of three main processes (Eckert DM, et al., Annu. Rev. Biochem. 2001, 70: 777-810): First, the surface glycoprotein gpl20 of the virus binds with high affinity to the cell surface receptor protein CD4 molecule.
  • the conformation changes to allow the virus to adsorb to the host cell; then, gpl20 interacts with host cell surface co-receptors (eg, CCR5, CXCR4, etc.), the conformation is further altered, and is isolated from gp41, and the gp41 N-terminal fusion peptide is inserted into the host cell membrane. Finally, the CHR region of gp41 (C-terminal heptad repeats) folds back and is close to the ⁇ -helix trimer formed by its NHR region (N_terminal heptad reats), forming a hexamer ⁇ _helix, which brings the virus and The distance of the cells leads to the fusion of the viral envelope with the cell membrane.
  • host cell surface co-receptors eg, CCR5, CXCR4, etc.
  • HIV entry inhibitors currently under study mainly target the viral surface glycoprotein gpl20/gp41 and the cell surface co-receptors CCR5/CXCR4 and CD4 receptors in the above process.
  • Entry inhibitors acting on gpl20 are (Thali M., et al., J. Virol. 1993, 67 (7): 3978-3988; Shaunak S., J. Pharmacol., 1994, 113: 151-158; Trkola A., et al., J. Virol. 1996, 70: 1100 - 1108; Wang T., et al., J. Med. Chem. 2003, 46: 4236-4239; Ferrer M., et al., J Virol. 1999, 73 (7): 5795-5802 ): 17b, 2G12, PR0542, BMS-378806, 12P1.
  • Inhibitors of entry into the CD4 receptor are (Reimann K. A., et al., ADIS Res. Hum. Retroviruses., 1997, 12 (11): 933-943): TNX-355
  • CCR5/CXCR4 is a molecule that exists on the surface of normal cells. In addition to being a co-receptor in the process of HIV virus entry, it is also a receptor for chemokines and inflammatory factors, so long-term competitive use of inhibitors can cause problems.
  • Some small molecule antagonists have found side effects on the heart during clinical studies (Maeda ⁇ , et al. , Curr. Opin. Pharmacol, 2004, 4 (5): 447-452).
  • Entry inhibitors that act on gpl20 are primarily antibodies that are screened or obtained from infected individuals with fewer small molecules. Currently, only 17b and 2G12 antibodies with broad neutralizing activity are obtained, and some of the other antibodies have neutralizing activity in vitro, but not in vivo.
  • the current small molecule inhibitor is BMS-378806, which binds to a hydrophobic pocket on gpl20, and the small peptide (12P1) obtained by peptide library screening may have the same binding site.
  • Inhibitors of entry into the CD4 receptor are currently the least studied because it is a very important molecule in vivo and its inhibition is likely to have serious side effects.
  • T-20 (trade name Fuzeon) is used in clinical practice.
  • T-20 is derived from the CHR region of the HIV-1 LAI strain gp41 and consists of 36 amino acids (Wild, C. T., et al, Pro Natl. Acad. Sci. U. S. A 1994, 91: 9770-9774).
  • the gp41 pre-fusion conformation can last for about 30 minutes, during which time T-20 can act on alpha-helix trimers formed by the NHR regions of three gp41 molecules (Melikyan GB, J. Cell. Biol., 2000, 151: 413-423).
  • T-20 prevents the CHR region of gp41 from binding to the NHR region, inhibiting the formation of helical hexamers, and thus the cell membranes of the virus and host are not close to each other, and the membrane fusion process is blocked.
  • T-20 cannot form stable helical hexamers in solution with the NHR region polypeptide N36 derived from gp41, so it may interact with multiple sites of gp41 and gpl20 (Liu S., et Al., J. Biol. Chem, 2005, 280(12): 11259-11273), which is different from its design principle.
  • T-1249 is the second generation of T-20, consisting of 39 amino acids, derived from HIV-1 LAI, HIV-2 NIHZ, SIV mac251; ⁇ CHR region (Schneider SE, et al, J. Pept. Sci. 2005, 11(11): 744-753).
  • CHR region a region of gp41
  • these strains are still sensitive to T-1249, which is thought to be possible to interact with the membrane.
  • Capacity-related (Veiga AS, et al, J. Am. Chem. Soc., 2004, 126(45): 14758-14763).
  • T-20, T-1249, TR-290999, and TR-291144 are currently the most effective peptide HIV fusion inhibitors, their common disadvantage is that molecular weight is larger than other anti-HIV drugs, making synthesis relatively difficult. .
  • a polypeptide-inhibiting virus fusion agent having a shorter amino acid sequence for synthesis; in addition, the fusion agent needs to have a different action site than T-20 to fight against T-20-resistant virus; Solubility and stability to enhance efficacy and reduce drug use.
  • the polypeptide has a short amino acid sequence, and the action site is different from the existing drug, and has good water solubility and high activity.
  • the surface glycoprotein of HIV-1 The NHR region of gp41 can be an ideal drug target because of its high degree of conservation, and the polypeptide derived from the CHR region can become a lead polypeptide of this drug because it can interact with the NHR region.
  • the viral fusion inhibitors provided by the present invention are derived from a CHR sequence of gp41 of the RL42 strain of the B' subtype, which is the most widely spread and most infective in mainland China, and has the following amino acid sequence:
  • the inventors designed a helical sequence that binds to the C-terminus of "Cavity" to increase the hydrophobic interaction with the gp41 NHR region; removed the sequence with weaker NHR binding ability to gp41, and introduced a hydrophilic amino acid to Increasing the water solubility of the inhibitor introduces an acidic or basic amino acid capable of generating an ionic bond at the "I” and "1+4" positions in the polypeptide sequence to increase the ability of itself to form a helix, which ultimately forms the present invention.
  • novel polypeptides of the general formula I have the effect of inhibiting viral fusion, and the primary structure of the polypeptide of the general formula I is as follows:
  • 3 ⁇ 4 is selected from any one of amino acids or vacancies of V, L, I, M;
  • X 2 is selected from any one of E, D, N amino acids or vacancies;
  • X 3 is selected from E, D, N of any amino acid
  • X 5 is selected from hydrazine or hydrazine
  • 3 ⁇ 4 is selected from any one of ⁇ , ⁇ or D;
  • 3 ⁇ 4 is selected from any one of D, E, K or R;
  • ⁇ is selected from an amide group, a carboxyl group or a carboxyl group derivative
  • D-aspartic acid ⁇ -glutamic acid; I-isoleucine; ⁇ -lysine; L-leucine; ⁇ -methionine; ⁇ -asparagine; Q-glutamine; R- Arginine; S-serine; ⁇ -threonine; V-guanidine; W-tryptophan; ⁇ -tyrosine.
  • One or more amino acids of the polypeptide of the present invention may be replaced with an amino acid having a conformational D-form, a rare amino acid present in nature, or an artificially modified amino acid to increase bioavailability and enhance inhibitory activity.
  • the amino acid of the D-form refers to an amino acid opposite to the amino acid constituting the L-form of the protein; rare amino acids present in nature include uncommon amino acids constituting the protein and amino acids not constituting the protein, such as: 5-hydroxylysine, methyl Histidine, ⁇ -aminobutyric acid, homoserine, etc.; Artificially modified amino acids refer to common L-type amino acids of constituent proteins modified by methylation, phosphorylation, and the like.
  • polypeptides of the invention may be linked to macromolecule carriers or polypeptides including, but not limited to, proteins, polyethylene glycols, lipids and the like.
  • the polypeptide of the present invention includes a modification of its truncated portion and its truncated portion.
  • the truncated portion of the above polypeptide is a peptide comprising 15-32 amino acids.
  • the cut-off portion of the modifier refers to a modification using polyethylene glycol, a chemical small molecule such as maleimide, and a modification of the protein.
  • a truncated portion of a modification refers to a derivative produced by the attachment of one or more amino acids of a polypeptide to polyethylene glycol, a chemical small molecule (e.g., maleimide), and a protein.
  • Polypeptides of the invention also include the above formula incorporating single and multiple amino acid inserts, substitutions and/or deletions.
  • the polypeptide of the present invention further includes the above polypeptide (Formula I) and its truncated polymer multimer, that is, several (1-4) identical polypeptides are passed through an amino acid such as lysine, cysteine, or the like. The molecules are joined together to form a multimer.
  • polypeptides of the formula I preferred are the following 18 polypeptides, the structures of which are as follows:
  • Peptide 1 NH 2 - SEQ ID No : l-C0NH 2
  • Polypeptide 2 N - SEQ ID No: 2- C0NH 2
  • Peptide 3 NH 2 - SEQ ID No : 3- C0NH 2
  • SEQ ID No: 3 VEWNNMTWMEWEREIENYTKLIYKILEESQEQ
  • Peptide 4 Ac- SEQ ID No : 4-C0NH 2
  • Peptide 5 Ac- SEQ ID No : 5-C0NH 2
  • SEQ ID No: 5 VEWNNKTWMEWEREIENYTKLIYKILEESQEQ
  • Peptide 6 NH 2 -NEKDLLEWMEWEREIENYTKLIYKILEESQEQ-CONH 2
  • Peptide 7 NH 2 -RINNIPWSEAMWMEWEREIENYTKLIYKILEESQEQ-CONH 2
  • Peptide 8 NH 2 - YDINYYT ⁇ EWERKIEEYTKLIYEILKKSQEQ- C0NH 2
  • Peptide 9 NH 2 - ( CEKNEQELLWMEWEREIENYTKLIYKILEESQEQCONH 2 ) 2
  • Polypeptide 10 NH2- SEQ ID No: 6_C0 NH 2
  • SEQ ID No : 7 ⁇ EMTWMEWEREIENYTKLIYKILEESQEQ Peptide 12: NH 2 - SEQ ID No : 8 - CO NH 2
  • Peptide 14 NH 2 - SEQ ID No : 10- CO NH 2
  • Peptide 15 NH 2 -WNNMTWMEWEREIENYTKLIYKILEESQEQ-CO NH 2
  • Peptide 16 NH 2 -WNNMTWMEWEREIENYTKLIYKILEESQEL-CO NH 2
  • Peptide 17 NH 2 -VEWNNMTWMEWEREIENYTKLIYKILEESQEL-C0 NH 2
  • Peptide 18 NH 2 -LEWNNMTWMEWEREIENYTKLIYKILEESQEL-C0 NH 2
  • polypeptides 1, 2, 3, 4, 5, 10, 11, 12, 13, 14 are particularly preferred.
  • the polypeptide provided by the present invention is significantly different in sequence structure from T-20, C34, T-1249 and the like.
  • the sequence of ⁇ -20 is: Ac- YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF- C0NH 2 (Wild, CT, et al, Proc. Natl. Acad. Sci. US A 1994, 91 : 9770 - 9774);
  • the sequence of C34 is Ac_WMEWDREINNYTSLHIS LIEESQNQQEKNEQELL-C0NH2 (Lu , M. , et al, J. Biomol.
  • T-1249 is WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF (Schneider SE et al, J. Pept. Sci. 2005, 11 (11) :744—753).
  • the present invention designs an active polypeptide which can bind to the viral surface glycoprotein gp41 according to the action mechanism of the HIV virus in the membrane fusion process and the receptor molecule on the cell membrane surface.
  • the site of action of the present invention is located on the hydrophobic "Cavity" domain of the trimer NHR on the gp41 molecule and at both ends, and can completely inhibit viral replication down to nanomolar concentrations.
  • T 20 and - 1249 are composed of 36 and 39 amino acids, respectively, and are synthesized by segmentation and then rejoined.
  • the anti-HIV fusion polypeptide provided by the present invention may consist of only 30 to 32 amino acids, but still has activity higher than T-20 and T-1249, and is easy to synthesize.
  • polypeptide sequence and site of action are different from existing drugs.
  • the polypeptide sequences of the present invention differ from T-20, T-1249 and other reported fusion polypeptide sequences (Jiang S., et al., Curr. Pharm. Des., 2002, 8(8): 563-580), The site of action is also different.
  • the reported polypeptides, such as T-20, C34, etc. mainly act on the hydrophobic "Cavity" of gp41 and its terminal binding.
  • the present invention mainly considers a sequence which binds to the sequence of the "Cavity" domain on the NHR region of the trimer of gp41 and the two ends thereof, and removes the sequence with weak binding ability.
  • a hydrophilic amino acid is introduced to increase the water solubility of the present invention, and an acidic or basic amino acid capable of generating an ionic bond is introduced at the "I” and "1+4" positions in the polypeptide sequence, so that the designed sequence has a strong The ability to form an alpha-helix to better bind to the above regions.
  • polypeptide of the present invention obtained by the above design has a much higher activity (about 500 times) than the activity of the natural peptide, wherein the activities of the polypeptides 3, 4, and 10 are higher than those of the existing polypeptide drug ⁇ -20 (see Example 4). Table 3), and the resistant strain of ⁇ -20 is still effective (see Example 5).
  • the polypeptide of the present invention is easily soluble in water, and the improvement of water solubility facilitates the improvement of the therapeutic effect of the drug and the development of the pharmaceutical dosage form.
  • the polypeptide of the present invention not only inhibits membrane fusion of HIV virus and cells, but also inhibits the entry of some enveloped viruses with similar membrane fusion processes into cells, such as: human respiratory syncytial virus (RSV), hepatitis Virus, etc.
  • RSV human respiratory syncytial virus
  • hepatitis Virus etc.
  • the polypeptide of the present invention can be produced by various methods such as solid phase synthesis, liquid phase synthesis, engineering bacterial expression and the like. For example, similar to the synthetic route of T-20, the peptide is first synthesized on the resin, and then the polypeptide is linked in the liquid phase to form the polypeptide of the present invention; the DMA sequence which can express the polypeptide of the present invention is synthesized or extracted, and is linked to a certain The polypeptide of the present invention is obtained by transfecting into a cell of a eukaryotic or prokaryotic organism, expressing a protein or polypeptide containing the polypeptide sequence provided by the present invention, and extracting and purifying it.
  • the polypeptide of the present invention can be directly used for the treatment of HIV infection, or can be used in combination with one or more anti-HIV drugs for the purpose of improving the overall therapeutic effect.
  • anti-HIV drugs are derived from, but are not limited to, one or more of a reverse transcriptase inhibitor, a protease inhibitor, and an entry and fusion inhibitor.
  • the above reverse transcriptase inhibitors include one or more of s AZT, 3TC, ddl, ddT, d4T, Abacavir, Nevirapine > Efavirenz Delavirdine.
  • the above protease inhibitors include: one or more of Saquinavir mesylate ⁇ Idinavir, Ritonavir, Amprenavir, Kaletra and Nelfinavir mesylate.
  • the above-mentioned entry and fusion inhibitors include: T-20, T-1249, C34, IQN37, 5_Helix, TAK_779, SCH-C, and naturally extracted proteins. Polypeptides having a function of inhibiting viral entry.
  • the drug containing the polypeptide of the present invention or a truncated substance, derivative and composition thereof can be administered directly to a patient, or can be administered to a patient in combination with a suitable carrier or excipient to achieve the purpose of treating HIV infection.
  • the carrier materials herein include: water-soluble carrier materials such as polyethylene glycol, polyvinylpyrrolidone, organic acids, etc.; poorly soluble carrier materials such as ethyl cellulose, cholesterol stearate, etc.; enteric carrier materials, For example, cellulose acetate phthalate and carboxymethylethyl cellulose are preferred as water-soluble materials.
  • the following dosage forms can be prepared: tablets, suppositories, solutions, capsules, aerosols, effervescent and drops, and the like, preferably solutions and aerosols.
  • the anti-HIV drugs and derivatives, truncates and analogs and compositions thereof provided by the present invention may be administered by injection, including intravenous injection, subcutaneous injection, intraluminal injection, etc.; Nasal administration; mucosal administration, such as nasal cavity, exerts systemic action on local or transmucosal absorption; intraluminal administration, such as transrectal and vaginal administration, local onset or absorption through the body.
  • the above administration route is preferably administered by injection.
  • Figure 1 shows the conformation of the helical conformation of N36 and Peptide 3 and the interaction between the two.
  • A is a complex
  • Climbing is Peptide 3
  • the country is 36;
  • Figure 2 is a schematic representation of the conformation of the helical conformation of N36 and polypeptide 6 and the interaction between the two, A is a complex, and the reference is a polypeptide 6, "is ⁇ 6;
  • Figure 3 is a diagram showing the conformation of the helical conformation of N36 and polypeptide 7 and the interaction between the two, A is a complex, and the reference is polypeptide 7, "" is ⁇ 6;
  • Figure 4 is a diagram showing the conformation of the helical conformation of N36 and polypeptide 9 and the interaction between the two; A is a complex, and the reference is polypeptide 9, which is ⁇ 6;
  • Figure 5 is a HPLC analysis diagram of polypeptide 3
  • Figure 6 is a gel HPLC analysis of polypeptide 4 and its complex with N36, in which 1 is a complex, 2 is a polypeptide 4, 3 is N36;
  • Figure 7 is a gel HPLC analysis of polypeptide 6 and its complex with N36, in which 1 is a complex, 2 is a polypeptide 6, and 3 is N36.
  • Figure 8 is a diagram showing the conformation of the helical conformation of N36 and polypeptide 10 and the interaction between the two.
  • A is a complex
  • ⁇ is a polypeptide 10, and is a country;
  • Figure 9 is a diagram showing the conformation of the helical conformation of N36 and polypeptide 12 and the interaction between the two, A is a complex, and the reference is polypeptide 12, and the country is ⁇ 6;
  • Figure 10 is a diagram showing the conformation of the helical conformation of N36 and polypeptide 13 and the interaction between the two.
  • A is a complex, and the reference is polypeptide 13, and
  • the polypeptide provided by the present invention can be synthesized on the ABI 433 solid phase synthesizer of Applied Biosystems, and the modification of the polypeptide is done manually.
  • the amino acid used in the synthesis was protected by Fmoc (product of Advanced Chemtech, USA), and the resin used was Rink resin (product of Advanced Chemtech, USA).
  • 1-hydroxybenzotriazole (HoBt) product of Advanced Chemtech, USA
  • ⁇ P N-methylpyrrolidone
  • DCC dicyclohexylcarbodiimide
  • the amount of Rink resin used and the amount of Fmc protected amino acid used are 1:5, and the protected amino acids are as follows: Fmoc-Ala-OH, Fraoc-Cys (Trt) -OH, Fmoc-As (OtBu) -OH, Fmoc-Glu ( 0tBu) _0H , Fraoc-Phe-OH, Fmoc-Gly-OH , Fmoc-His (Trt) -OH , Fmoc-Ile-OH , Fmoc-Lys (Boc) -OH , Fmoc-Leu-OH , Fmoc-Met- OH , Fmoc-Asn (Trt) -OH , Fmoc- Pro- OH, Fmoc- Gin (Trt) -OH, Fmoc-Arg (Pbf) -OH , Fmoc-Ser (tBu) -OH ,
  • the N-terminus was acetylated by an artificial method.
  • Peptide resin, N-methylpyrrolidone (NMP) (8-15 times the weight of the peptide resin), acetic anhydride (0.5 ml of lg resin), diisopropyl acetamide (diisopropylacetamide) was added to the reaction chamber.
  • DIEA 0.7 ml of lg resin
  • reacted at room temperature for 2 hours filtered, and the resin was washed three times with dichloromethane, methanol and N-methylpyrrolidone (just P).
  • the above-mentioned synthesized lysate for resin composition: bisthylthreitol (DTT) 5%, water (5%), trifluoroacetic acid (TFA) 88%, and triisopropylsilane (TIPS) 2%)
  • the ratio of the amount of the resin to the lysate is: 0. 5- 1. 0 g of resin / 10 ml of lysate) cleavage 2. 5 ⁇ 3. 0 hours, filtered, and the filtrate is evaporated to remove most of the trifluoroacetic acid by a rotary evaporator. Precipitation was carried out with pre-cooled anhydrous diethyl ether, filtered to give a preliminary peptide, which was dissolved in dilute aqueous ammonia and the filtrate was lyophilized.
  • the above lyophilized crude peptide was purified by reverse-phase HPLC, and the purification column was a reverse phase C 18 semi-preparative column (Zorbax, 300 SB-C18, 9. 4 awake x 25 cm), and the gradient eluent was acetonitrile with different gradients (including 0. 1% TFA) / water (containing 0.1% TFA), the target peak was collected, most of the acetonitrile was removed by rotary evaporation, and lyophilized to give a pure peptide.
  • the molecular weight of each polypeptide was determined by matrix-assisted laser desorption ionization mass spectrometry (MALDI-T0F-MS Reflex III, Micromass), and the results were in agreement with theoretical calculations.
  • the G4 glass core funnel was filtered to obtain the initial peptide, and the solid was dissolved in 1% diluted aqueous ammonia, and the filtrate was lyophilized to obtain a crude peptide of 0.33 g, and the purity was about 60%.
  • the crude peptide was purified by HPLC, and the column was a reverse phase C 18 semi-preparative column (Zorbax, 300 SB-C18, 9. 4 mm x 25 cra mobile phase: A, acetonitrile (containing 0.1% TFA); B, water (Including 0.1% TFA).
  • the elution gradient is: 1- 5min 10-45% A; 5-30 min, 45-65% A, flow rate 3 ml / min, UV 214 nm detection, 5 mg per load
  • the target fractions were collected, and most of the acetonitrile was removed by rotary evaporation, and lyophilized to give 20 mg of pure peptide.
  • the molecular weight of the mass spectrometry was 4163. 20 Da (theoretical calculated value 4162. 67 Da).
  • Each of the polypeptides provided by ⁇ 36 and the present invention was dissolved in water at a concentration of 2.5 mM, and then diluted to 10 ⁇ 3 ⁇ 41 in phosphate buffer to determine the secondary structure under the above parameters. Then, an equal amount of hydrazine 36 and the present invention were mixed, and then diluted to a respective concentration of 10 ⁇ in a phosphate buffer solution, and incubated in a 37 ° C water bath for 30 minutes, and the mixture after the incubation was separately measured under the above parameters. Level structure.
  • Figure 1- ⁇ shows the change in the helical conformation of N36 and the interaction of polypeptides 3, 6, 7, 9, 10, 12, and 13, respectively, and the HPLC analysis of the above polypeptide.
  • a typical ⁇ -helix shows a double negative peak at 208 nm and 222 nm on the CD map.
  • Figures 1 to 4 and Figures 8 to 10 show changes in the conformation of N36 and the helical conformation of the polypeptide of the present invention and the interaction between the two.
  • the polypeptide of the present invention interacts with N36 derived from the HIV gp41 NHR region, and the complex of the two forms a distinct negative peak at 220 nm.
  • Molar optical rotation of the composite [ ⁇ Calculated as follows: lO x n x C x L
  • ⁇ is the ellipticity value (in mdeg) measured on a circular dichroic chromatograph
  • n is the number of residues in the polypeptide, (the number of residues in the complex is 1/2 of the sum of the number of two peptide residues) Calculate)
  • C is the molar concentration of the polypeptide (the concentration of the complex is calculated as ⁇ ⁇ ⁇ )
  • L is the optical path of the quartz cup, in centimeters.
  • polypeptides provided by the present invention increase the amount of helix after interaction with hydrazine 36 in solution, indicating that these polypeptides interact with hydrazine 36 and form a complex, and the spiral formation tendency of the complex increases.
  • the aim is to demonstrate whether there is a strong interaction between the two by detecting whether the polypeptide of the invention binds to ⁇ 36.
  • the substance is separated by the molecular weight, and the substance having a large molecular weight is first eluted.
  • the polypeptide forms a complex with ⁇ 36, it will elute first when the molecular weight is increased. If the complex is not formed, the mixture will form two equal-high peaks corresponding to the polypeptide and oxime 36 provided by the present invention.
  • polypeptide provided by the invention can form a multimeric complex with N36 in phosphate buffer, indicating a strong interaction between the two.
  • Example 4 Inhibition of HIV by the polypeptide of the present invention
  • the multifunctional HIV entry inhibitor provided by the present invention has an effect of inhibiting fusion of a virus and a cell membrane, and is determined by the following experiment.
  • the cells and viruses used are from the US NIH AIDS Research and Reference Reagent Program.
  • HIV-1 prion-infected human lymphocytes H9 were stained with the fluorescent dye Calcein-AM (Molecular Probes, Inc., Eugene, OR) and then mixed with human lymphocyte MT-2 in a certain ratio and then applied to a 96-well plate.
  • the 9 polypeptides of the present invention (see Table 3) were separately added and cultured at 37 ° C for 2 hours, using cells to which no polypeptide of the present invention was added as a control. Observation unfused and fused cells in the scale with a fluorescence inverted microscope (Zeiss, Germany) and counted using GraphPad Prism software (GraphPad Software Inc., San Diego, CA) and half the amount calculated percentage fusion inhibitor (IC 5. ), 90% inhibitor amount (IC 9 .). (Jiang S, et al. Procedings of SPIE. 2000, 3926, 212-219. and Jiang S, et al. J. Virol. Meth. 1999, 80, 85-96.) The results are shown in
  • Human lymphocytes MT-2 were suspended in RPMI-1640 medium (Gibco Laboratories, Grand Island, NY) containing 10% fetal bovine serum (Gibco Laboratories) at a cell density of 5 x 104 cells/ml, and then plated at a volume of each well. 200 ⁇ 1 . Take 100 times TCID 5 . (half the infectious dose) Concentration of HIV-1 prions was infected.
  • the polypeptide well of the present invention was added to the above-mentioned infected virus medium by gradient dilution, and the well without the polypeptide of the present invention was used as a control, followed by culturing overnight. The next day was changed to fresh medium.
  • VN virus neutralization test / viral neutralization
  • Peptide purity The polypeptides used in cell fusion and neutralization experiments were purified, except for peptide 4 (purity 70%) with a purity greater than 90%. In the test, T-20 was used as a control, and the purity of the latter was more than 95%.
  • Example 5 Inhibition of fusion of a polypeptide of the present invention against a T-20 resistant HIV cell line
  • the polypeptide 3 provided by the present invention can completely inhibit the replication of the virus in cells at 1.0 ⁇ M, while the T-20 is

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur une classe de peptides inhibiteurs de la fusion du VIH. Sur la base du mécanisme d'action de l'enveloppe du VIH avec les cellules réceptrices des membranes cellulaires, pendant la fusion entre les membranes virales et celles des cellules cibles, les peptides actifs pouvant se fixer à la glycoprotéine gp41 de l'enveloppe du VIH ont été identifiés. Les sites d'action desdits polypeptides sont situés dans la 'cavité longue' du côté du NHR trimère, et les deux terminaux de la gp41 inhibent ainsi efficacement la réplication du VIH. Par rapport aux médicaments actuels, lesdits peptides ont un poids moléculaire moindre, une activité biologique améliorée et une meilleure solubilité dans l'eau. Les peptides inhibiteurs de la fusion du VIH peuvent servir à inhiber les infection par différents virus à enveloppe.
PCT/CN2006/001323 2005-12-14 2006-06-14 Peptides inhibiteurs de la fusion du vih et leur utilisation WO2007068163A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNA2005101264737A CN1793170A (zh) 2005-12-14 2005-12-14 抑制hiv病毒融合的多肽及其用途
CN200510126473.7 2005-12-14

Publications (1)

Publication Number Publication Date
WO2007068163A1 true WO2007068163A1 (fr) 2007-06-21

Family

ID=36804829

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2006/001323 WO2007068163A1 (fr) 2005-12-14 2006-06-14 Peptides inhibiteurs de la fusion du vih et leur utilisation

Country Status (2)

Country Link
CN (1) CN1793170A (fr)
WO (1) WO2007068163A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102089329B (zh) * 2008-06-25 2014-10-15 中国人民解放军军事医学科学院毒物药物研究所 抑制hiv感染的多肽及其衍生物
CN102247590A (zh) * 2010-05-18 2011-11-23 天津市扶素生物技术有限公司 用于预防或治疗hiv感染的药物组合及其应用
CN102180951B (zh) * 2011-05-03 2012-09-26 中国医学科学院病原生物学研究所 胆固醇修饰的抗hiv多肽药物及其用途
CN117186187B (zh) * 2023-07-12 2024-05-31 中国医学科学院病原生物学研究所 一种抗呼吸道合胞病毒膜融合抑制剂及其药物用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005067960A1 (fr) * 2004-01-07 2005-07-28 Trimeris, Inc. Peptides synthetiques derives de la hr2 de la gp41 du vih, et leur utilisation dans une therapie destinee a inhiber la transmission du virus de l'immunodeficience humaine
WO2005080418A2 (fr) * 2004-02-23 2005-09-01 Borean Pharma A/S Inhibiteurs de fusion du vih multimerises
CN1668330A (zh) * 2002-09-24 2005-09-14 重庆前沿生物技术有限公司 Hiv感染的肽衍生物融合抑制剂
WO2005089796A1 (fr) * 2004-03-15 2005-09-29 Trimeris, Inc. Modification chimique specifique de site de peptides derives de gp41 du vih

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1668330A (zh) * 2002-09-24 2005-09-14 重庆前沿生物技术有限公司 Hiv感染的肽衍生物融合抑制剂
WO2005067960A1 (fr) * 2004-01-07 2005-07-28 Trimeris, Inc. Peptides synthetiques derives de la hr2 de la gp41 du vih, et leur utilisation dans une therapie destinee a inhiber la transmission du virus de l'immunodeficience humaine
WO2005080418A2 (fr) * 2004-02-23 2005-09-01 Borean Pharma A/S Inhibiteurs de fusion du vih multimerises
WO2005089796A1 (fr) * 2004-03-15 2005-09-29 Trimeris, Inc. Modification chimique specifique de site de peptides derives de gp41 du vih

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARKOSYAN R.M. ET AL.: "The mechanism of inhibition of HIV-1 env-mediated cell-cell fusion by recombinant cores of gp41 ectodomain", VIROLOGY, 2002, pages 174 - 184, XP002244463 *

Also Published As

Publication number Publication date
CN1793170A (zh) 2006-06-28

Similar Documents

Publication Publication Date Title
JP4682251B2 (ja) 改善された生物学的特性を有するｈｉｖ融合阻害剤ペプチド
JP2010505831A (ja) 安定化した、治療用の小型のヘリックス性抗ウイルスペプチド
JPH06340698A (ja) Ｈｉｖ−１ のインヒビターとしての合成ポリペプチド
CN111944025B (zh) 艾滋病病毒膜融合抑制剂脂肽及药物用途
Schneider et al. Development of HIV fusion inhibitors
CN106749558B (zh) 广谱抑制hiv的脂肽、其衍生物、其药物组合物及其用途
JP7057822B2 (ja) Ｈｉｖを強力に阻害するためのリポペプチド、その誘導体、その医薬組成物及びその使用
CN100455594C (zh) 抑制hiv病毒融合的多肽及其用途
WO2007068163A1 (fr) Peptides inhibiteurs de la fusion du vih et leur utilisation
Geng et al. Characterization of novel HIV fusion-inhibitory lipopeptides with the MT hook structure
WO2013075594A1 (fr) Polypeptide anti-infection par le vih conçu artificiellement, composition et utilisation associées
Lee et al. Structure-activity relationships of anti-HIV-1 peptides with disulfide linkage between D-and L-cysteine at positions i and i+ 3, respectively, derived from HIV-1 gp41 C-peptide
JP3369585B2 (ja) ヒト免疫不全ウイルスの群特異性抗原の選択されたペプチド、その調製および使用
WO2018141089A1 (fr) Lipopeptide à large spectre d'inhibition du vih, dérivés de celui-ci, compositions pharmaceutiques et utilisation associées
EP1669368A1 (fr) Utilisation de peptides de la protéine E2 du virus de l'hépatite C (HCV) pour traiter les infections à HCV
EP1621203A1 (fr) Peptides inhibant l'ARNIII pour le traitement d'une infection de vih

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06742168

Country of ref document: EP

Kind code of ref document: A1